作者
Qingqi Hong,Jingtao Zhu,Hexin Lin,Yinan Chen,Haoyu Bai,Linghua Yan,Xiao Li,Jun You
摘要
Comprehensive genomic analysis of molecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancerDear Editor, Colorectal cancer (CRC) is a major global health issue with a 40% 5-year mortality rate, 1 and 30%-50% of patients still experience recurrence after curative resection.2,3 The clinical utility of molecular residual disease (MRD) detection in risk stratification and recurrence detection using circulating tumour DNA (ctDNA) noninvasively has attracted widespread attention but with limited studies.4-7 We measured the value of tumour-agnostic ctDNA-guided MRD for recurrence prediction and monitoring, and explored the biological characteristics of ctDNA from MRD.We included 104 patients with stage I-IV CRC (Figure S1), aged 26 to 82 years.Fourteen (13.5%) patients had positive landmark MRD, and thirty-two (30.8%) patients had positive longitudinal MRD (Table S1).The most frequently variant genes in tumour tissue were TP53, KRAS and APC (Figure S2A), while in ctDNA were KRAS, EGFR and TP53 (Figure S2B).Patients with negative landmark MRD had a lower recurrence percentage than positive cases (11.1% vs. 57.1%,p < .001),yielding a negative predictive value (NPV) of 88.9% (Figure 1A).The latter group had a significantly higher recurrence risk (hazard ratio [HR], 7.325; p < .001, Figure 1B).As for longitudinal MRD, the recurrence percentage was higher in positive-MRD compared to negative-MRD (43.8% vs. 5.6%, p < .001),yielding a high NPV (94.4%, Figure 1C).Positive longitudinal MRD was correlated with an elevated risk of recurrence (HR: 9.385; p < .001, Figure 1D).In multivariate analysis for disease-free survival (DFS), landmark and longitudinal MRD-positive were significantly associated with increased recurrence risks (Figure 1E).Furthermore, we explored the effect of longitudinal MRD status in patients receiving and not receiving neoadjuvant therapy (NAT).In both groups, longitudinal positive-MRD patients had higher recurrence risk than negative-MRD patients (NAT: HR, 12.509,